Solid YoY growth masks sequential profit collapse and margin flatness

259.8 Cr Q1 FY27 vs ~225 Cr Q1 FY26 = 15.2% YoY

19.8 Cr / 260 Cr = 7.61%; vs 6.89% Q4 FY26 = 72 bps improvement

Stated by management, not contradicted; consistent with volume outpacing realization

PAT 2.51 Cr this quarter vs 3.98 Cr prior quarter = –37% QoQ decline; contradicts 'recovery'

Q1 FY27: 7.62% vs Q1 FY26: 8.01% = –39 bps YoY; management blames RM inflation

Mahad at 50–60% utilization, ~₹3 Cr quarterly revenue (~₹12 Cr annualized), still loss-making

Prior FY26 calls: Mahad ₹50–65 Cr at optimal utilization as FY27 driver. Actual Q1 FY27: ₹3 Cr quarterly (~₹12 Cr annualized) at 50–60% utilization. No acceleration timeline given; management vague ('promising early approvals').

Prior FY26 call: 'Progressive margin improvements through cost programs in FY27.' Actual: EBITDA margin 7.62% vs 8.01% YoY (–39 bps). Raw material inflation now seen as 'ongoing' headwind, not transitory.

Q1 FY27 exports: 35% of revenue vs 33% FY26 prior year. Management expects to 'maintain' range; no material shift.

Management cites West Asia crisis impact on Alpha-Pinene sourcing, FX volatility, customer pre-buying behavior. Operationalized as risk to pricing power and supply continuity.

Mahad 50–60%, others 85–90%. Fragrance compounding has 'substantial' additional capacity. Long-term peak deferred to CFO (Girish) off-call.

Margins 'very fluid' given geopolitical uncertainty; no forward guidance. Cautious on Alpha-Pinene and petro pricing volatility. Watching 'very closely.'

No development since prior call. Won't disclose segment contribution (strategy to keep opaque).

Gap driven by customer pre-buying due to geopolitical concerns, raw material price lags, and product mix. Going forward will balance volume growth with 'decent contribution margin.'

Realistic to demand-supply gap; industry cooperation unlikely. 'Wishful thinking.' Each player chasing share of non-growing pie.

Camphor powder up double-digit %. Alpha-Pinene up 70–80% over 5 months, continues 'firm.' Imported in USD, so FX also a factor.

Q1 FY27 exports 35% vs 33% prior year. Will maintain range; no material change expected.

Long monologue: Backward integration into Fragrance division is the 'critical piece' investors miss. CAPEX enables margin and strategic moat, not just ingredient sales. Fragrance value creation doesn't need CAPEX, needs pricing power and innovation. Deferred specifics to off-call conversation.

Inventory buildup due to raw material access challenges (petro-driven); confident will sell. Mahad 'Phase-1' only; large site for future molecules. Generics pressure is industry-wide. Confidence in margin recovery when capacity utilization improves and pricing cycle resets (no timeline).

Long-term supplier relationships and vigilant communications. Dedicated team managing long/short buying across all raw materials and divisions. Hit 'last and lowest' on volatility.

Parag Satoskar stated as 'near-term goal' but not formalized. Anchored on Q1 15.2% YoY, Q2/Q3 seasonal strength, and 'active customer pipeline.'

Mahad-only ₹12 Cr annualized revenue at 50–60% utilization is far below prior ₹50–65 Cr guidance. Commercialization cycle 500–1,000 days (5–33 months) is undefined. No timeline given for EBITDA neutrality or 75–80% utilization targets. Continues to drag consolidated profitability.

Alpha-Pinene prices up 70–80% over 5 months and 'firm.' Petro-driven inputs volatile. EBITDA margin flat YoY at 7.62% vs 8.01% despite operational efficiency gains, indicating margin compression masked by cost recoveries. Pricing pass-through limited by buyer's market in ingredients.

Specialty aroma ingredients and camphor segments face structural overcapacity from capacity additions across Asia, particularly China. Industry is a 'buyer's market' with customers demanding competitive pricing, high quality, innovation, and supply security. Capacity-to-demand growth mismatch indefinite.

Net profit margin of 1.0% (₹2.5 Cr on ₹260 Cr revenue) leaves zero room for error. Sequential PAT volatility: –36.9% QoQ (₹2.51 Cr vs ₹3.98 Cr). One bad quarter, a revenue miss of 5–10%, or unexpected cost shock immediately erases earnings. Shareholders bear execution risk.

Sequential decline: Revenue –8% QoQ, PAT –36.9% QoQ. Management attributes to product mix and seasonality but underscores quarter-to-quarter variability. YoY comparisons on low Q1 FY26 base (₹0.5 Cr PAT) mask underlying weakness.